Safe and Effective Prescribing of Opioid Analgesics: A Hands-on, Case-based Clinical Curriculum in Primary Care
Release Date: July 26, 2019
Expiration Date: December 02, 2020
Expected time to complete this activity as designed: 180 minutes
There are no fees for participating in or receiving credit for this online activity.
This activity is designed for physicians, physician assistants, nurses, pharmacists, dentists, and allied health professionals whose practices manage acute and chronic pain.
Upon completion of this educational activity, participants should be able to:
- Apply principles of pain pathophysiology and management in the development of individualized treatment strategies for patients with acute and chronic pain
- Effectively assess patients who are candidates for treatment with IR or ER/LA opioids
- Compare and contrast analgesic options for acute and chronic pain, including non-pharmacologic strategies, non-opioids, and IR and ER/LA opioids
- Demonstrate how to initiate therapy, modify dose, and discontinue use of IR and ER/LA opioid analgesics within a strategic treatment plan
- Integrate knowledge of IR, ER, LA, and abuse-deterrent formulation (ADF) opioids into individualized short- and long-term treatment plans that maximize safety and efficacy
- Counsel patients and caregivers regarding the safe use of both IR and ER/LA opioid analgesics, including storage and disposal
- Identify principles of addiction medicine and an understanding of opioid use disorder in managing patients who may be prescribed IR or ER/LA opioids
IR Opioids for Acute Pain Management – Jeffrey A. Gudin, MD, and Charles P. Vega, Jr., MD, FAAFP
ER/LA Opioids for Chronic Pain Management – Jeffrey A. Gudin, MD, and Charles P. Vega, Jr., MD, FAAFP
Opioids, Pain Management and Addiction – Martin D. Cheatle, PhD, and Charles P. Vega, Jr., MD, FAAFP
Instructions for Participation and Credit
This activity is eligible for credit through July 26, 2020. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
|Martin D. Cheatle, PhD
|Jeffrey A. Gudin, MD
|Charles P. Vega, Jr., MD, FAAFP
|David S. Craig, PharmD
Martin D. Cheatle, PhD
Associate Professor of Psychology in Psychiatry
Department of Psychiatry
Perelman School of Medicine, University of Pennsylvania
Dr. Martin Cheatle received his PhD in psychology at Princeton University and completed an NIH research fellowship and clinical internship/residency at the Hospital of the University of Pennsylvania. He is an Associate Professor of Psychology in Psychiatry at Perelman School of Medicine, University of Pennsylvania, Philadelphia. In addition, Dr. Cheatle is Director of Behavioral Medicine at the PENN Pain Medicine Center and Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction, University of Pennsylvania.
Dr. Cheatle holds membership in the International Association for the Study of Pain, Society of Behavioral Medicine, American Psychological Association, American Pain Society, and is a fellow and diplomate of the American Board of Medical Psychotherapists. He is on the editorial board of Pain Medicine, the Opioids and Substance Use Disorders section editor at Pain Medicine, and is an ad hoc reviewer for numerous medical journals.
Dr. Cheatle specializes in the evaluation and treatment of chronic pain disorders from a biopsychosocial perspective and has been involved in extensive research on the development of addiction in patients on prescription opioid therapy for chronic pain, and assessing phenotypic and genotypic markers of prescription opioid abuse. His main focus of research is pain management and addiction in vulnerable populations (HIV/AIDS, psychiatric patients) and pain and suicidal ideation and behavior.
Jeffrey A. Gudin, MD
Director, Pain Management and Wellness Center
Clinical Associate Professor of Anesthesiology
Rutgers New Jersey Medical School
Newark, New Jersey
Dr. Jeff Gudin received his medical degree from Albany Medical College in Albany, New York. He completed his residency in anesthesiology at the Yale University School of Medicine and his fellowship at The Yale Center for Pain Management, New Haven, Connecticut. While in New Haven, he also trained in addiction medicine and directed a substance abuse treatment center. For the past 19 years, Dr. Gudin was Director of Pain Management and Palliative Care at Englewood Hospital and Medical Center. He is now a Clinical Associate Professor of Anesthesiology at the Rutgers New Jersey Medical School. He remains active in teaching and research, and has lectured internationally on a variety of topics in pain management, palliative care, and addiction medicine.
Dr. Gudin is board certified in pain management, anesthesiology, addiction medicine, and hospice and palliative medicine. In addition, he is a medical acupuncturist and the former New Jersey State Representative for the American Academy of Pain Medicine. Dr. Gudin has dedicated his career to promoting education in pain management. He attends and has presented at the American Pain Society, American Academy of Pain Management, American Academy of Physical Medicine and Rehabilitation, as well as many other national venues. He serves as a consultant to state medical boards on challenging cases, as well as to industry on novel analgesic products and risk management associated with opioids.
Dr. Gudin is recognized nationally as a leader in pain management. He is an experienced researcher, consultant, speaker, and speaker trainer. He has collaborated with numerous initiatives to enhance responsible prescribing and the safe use of opioid pain medications.
Charles P. Vega, Jr., MD, FAAFP
Health Sciences Clinical Professor
University of California, Irvine
Dr. Charles Vega received his medical degree at the University of Wisconsin–Madison and completed residency training in family medicine at the University of California, Irvine (UCI) where now holds the title of Health Sciences Clinical Professor. He is the Executive Director of UCI’s Program in Medical Education for the Latino Community and won a Macy Faculty Scholarship to improve patient-centered health education at UCI. He assumed the role of Associate Dean for Diversity and Inclusion at the UCI School of Medicine in July 2016.
Dr. Vega has seen patients and taught medical students and residents at UC Irvine’s Family Health Center–Santa Ana for the past 20 years. This clinic is a federally qualified health center and the largest safety-net clinic for Orange County. Dr. Vega’s academic interests are focused on access to quality, compassionate medical care for underserved populations, and the development of training programs to promote this vision of health care.
David S. Craig, PharmD
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy
Pain Management and Palliative Care Services
Moffitt Cancer Center and Research Institute
Dr. David Craig received his doctor of pharmacy degree from the University of Tennessee. He completed his pharmacy practice residency at Duke University Medical Center and his pain and palliative care specialty residency at H. Lee Moffitt Cancer Center and Research Institute. Dr. Craig is a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy, as well as Pharmacist Lead in Supportive Care Medicine at the Moffitt Cancer Center.
Dr. Craig is a member of the American Pain Society and holds editorial board positions at Pharmacy Practice & Pain Medicine News, Practical Pain Management, and the Journal of Pain & Palliative Care Pharmacotherapy.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 3.0 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-19-006-H01-P. Application-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 3.0 contact hours. Program Number: 19-006-096
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Martin Cheatle has received honoraria as a consultant from Rockpointe Corporation.
Dr. Jeffrey Gudin has received honoraria related to speakers’ bureau activities from AstraZeneca, Daiichi Sankyo Company Limited, Salix Pharmaceuticals, and SCILEX Pharmaceuticals, Inc., and formal advisory activities from AcelRx Pharmaceuticals, Inc., BioDelivery Sciences International, Inc., and Recro Pharma, Inc., as well as consultant fees from Averitas Pharma, Inc., Mallinckrodt Pharmaceuticals, Nektar, PERNIX Therapeutics, Quest Diagnostics, and SCILEX.
Dr. Charles Vega has disclosed no relevant financial relationships.
Dr. David Craig has received consultant fees from Nektar Therapeutics and SpecGx LLC
Andrew Bowser has disclosed that his spouse/life partner has received honoraria related to speaker’s bureau activities from Takeda Pharmaceutical Company Limited and as a consultant from ALK-Abelló A/S, CSL Behring, Pharming Group NV, and Shire.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke and Andrea Mathis, Project Managers, Andrew Bowser, Medical Writer, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.